A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

• Status: Unknown status
• Trial end date: 2019-11-30
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter, randomized, double-blind, parallel, phase 2 study to assess dose-response relationship of HCP1803 in patients with essential hypertension

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hanmi Pharmaceutical Company Limited
• Treatments: Amlodipine; Losartan

Criteria

Inclusion Criteria:

• Patient with essential hypertension who meet 140 mmHg ≤ mean sitSBP < 180 mmHg and mean sitDBP < 110 mmHg at Visit 1, Visit 2

Exclusion Criteria:

• Patient with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1

• Patient with difference of ≥ 15 mmHg in mean sitSBP between Visit 1 and Visit 2

• Patient with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg at Visit 1, Visit 2

• Patient with secondary hypertension